




Summary of Consolidated Financial Results For Fiscal 2009

Forecasts of Consolidated Financial Results For Fiscal 2010



Hiroshi Takahara
Corporate Officer
Senior Vice President
Finance & Accounting Department

Takeda Pharmaceutical Company Limited

FY2009 Consolidated Results Summary

	FY08	FY09	Year-on-year change	
	billions of yen	billions of yen	billions of yen	
Net Sales	1,538.3	1,466.0	- 72.4	- 4.7%
Gross Profit	1,248.8	1,180.9	- 67.9	- 5.4%
SG&A Expenses	489.3	464.3	- 25.0	- 5.1%
Excluding Intangible Fixed Assets & Goodwill Amortization Costs	405.9	383.9	- 22.1	- 5.4%
R&D Expenses	453.0	296.4	- 156.7	- 34.6%
Excluding IPR&D Expenses	293.2	296.4	+ 3.2	+ 1.1%
Operating Income	306.5	420.2	+ 113.7	+ 37.1%
Excluding Extraordinary Factors	549.9	500.9	- 49.0	- 8.9%
Ordinary Income	327.2	415.8	+ 88.6	+ 27.1%
Net Income	234.4	297.7	+ 63.4	+ 27.0%
Excluding Extraordinary Income/Loss & Other Extraordinary Factors	380.4	354.3	- 26.1	- 6.9%
E P S *	470.30 yen	448.81 yen	- 21.49 yen	- 4.6%
RO E	10.9%	14.4%	+ 3.5 pt	

* Excluding Extraordinary Income/Loss & Other Extraordinary Factors

2

Takeda Pharmaceutical Company Limited

FY2009 Consolidated Results Summary (comparison with forecasts)

(Unit: billions of yen)

	FY 2009 Forecasts As of May 2009	FY 2009 Forecasts As of Feb. 2010 ①	FY 2009 Actual Results ②	Comparison with Forecasts	
				③=②-①	③÷①
Net Sales	1,500.0	1,480.0	1,466.0	-14.0	<-0.9%>
Operating Income	395.0	395.0	420.2	+25.2	<+6.4%>
Ordinary Income	400.0	400.0	415.8	+15.8	<+4.0%>
Net Income	280.0	280.0	297.7	+17.7	<+6.3%>
R&D Expenses	310.0	310.0	296.4	-13.6	<-4.4%>

3

Takeda Pharmaceutical Company Limited

Currency Translation Effect (Comparison with FY2008)


(Unit: billions of yen)

	Year-on-year Increase / Decrease	Currency Translation Effect (Year-on-year Increase / Decrease)				Year-on-year Increase / Decrease Excluding Currency Translation Effect
		Total	US\$	Euro	Others	
			$\left(\begin{array}{l} 1\text{US\$ } 101\text{yen} \\ \rightarrow 93\text{yen} \\ - 8 \text{ yen} \end{array} \right)$	$\left(\begin{array}{l} 1\text{Euro } 143\text{yen} \\ \rightarrow 131\text{yen} \\ - 12 \text{ yen} \end{array} \right)$		
Net Sales	- 72.4	- 64.7	- 50.0	- 9.7	- 5.0	- 7.7
SG&A Expenses	- 25.0	- 28.1	- 22.3	- 3.6	- 2.1	+ 3.1
R&D Expenses	- 156.7	- 18.0	- 13.5	- 0.3	- 4.2	- 138.6
Operating Income	+ 113.7	- 17.8	- 14.3	- 4.8	+ 1.3	+ 131.6
Net Income	+ 63.4	- 11.6	- 8.7	- 4.2	+ 1.3	+ 75.0

4


Takeda Pharmaceutical Company Limited

Breakdown of Sales Increase/Decrease by Business Segments



Consolidated Ethical Drugs Sales by Region

(excluding sales of products for which Takeda acts as a distributor)



Main Products Sales (Consolidated Basis)


(Unit: billions of yen)

	FY2008	FY2009	Year-on-year change		Regional Increase/Decrease			
					Japan	Americas	Europe	Asia
Pioglitazone	387.0	384.7	- 2.3	< - 0.6% >	+ 3.9	- 4.3	- 1.6	- 0.2
			[excl. CTE +26.2] (CTE stands for Currency Translation Effect)					
Sales of Pioglitazone in the U.S. (\$MM)	< 2,998 >	< 3,193 >	< +194 >	< + 6.5% >	—	< +194 >	—	—
Lansoprazole	271.4	218.1	- 53.3	< - 19.6% >	+ 3.5	- 54.1	- 3.2	+ 0.4
			[excl. CTE -42.0]					
Sales of Lansoprazole in the U.S. (\$MM)	* < 1,771 >	< 1,205 >	< -565 >	< - 31.9% >	—	< -565 >	—	—
Candesartan	230.3	222.0	- 8.4	< - 3.6% >	- 1.7	Overseas total -6.7		
			[excl. CTE +0.9]					
Leuprorelin	126.1	122.2	- 4.0	< - 3.2% >	+ 0.7	- 1.4	- 3.6	+ 0.4
			[excl. CTE -0.9]					
VELCADE	37.7	46.2	+ 8.5	< + 22.6% >	—	+ 8.5	—	—
			[excl. CTE +12.4]					
Sales of Velcade in the U.S. (\$MM)	* < 409 >	< 498 >	< +89 >	< + 21.7% >	—	< +89 >	—	—


* Sales in local currency include sales for Apr FY2008 before consolidation of TAP and Millennium

Takeda Pharmaceutical Company Limited

Breakdown of Operating Income Increase/Decrease



Breakdown of Net Income Increase/Decrease



Consolidated Cash Flow Summary

(Unit: billions of yen)

	FY2008	FY2009
Net cash provided by (used in) operating activities	326.3	381.2
Net income before income taxes and minority interests	398.5	415.8
Depreciation of tangible fixed assets and amortization of patents	103.2	99.8
Amortization of goodwill	14.9	15.1
IPR&D expenses and gain from transfer of the Lupron business	88.5	—
Increase/decrease in working capital	-36.9	14.1
Income taxes paid	-220.4	-138.7
Net cash provided by (used in) investing activities	-767.3	-117.5
Payment for acquisition of subsidiaries' shares	-833.5	-6.9
Net cash provided by (used in) financing activities	-425.8	-148.0
Payment for treasury stock buyback	-280.3	-0.0
Dividends paid	-142.4	-143.6
Effect of exchange rate changes on cash and cash equivalents	11.7	-21.2
Net increase (decrease) in cash and cash equivalents	-855.2	94.4
Cash and cash equivalents, end of period	758.1	852.5

Takeda Pharmaceutical Company Limited

FY2010 Forecasts Financial Summary

	FY2009 Billion yen	FY2010 Billion yen	Year-on-year change	
			Billion yen	(%)
Net sales	1,466.0	1,400.0	- 66.0	< - 4.5>
Operating income	420.2	330.0	- 90.2	< - 21.5>
Ordinary income	415.8	340.0	- 75.8	< - 18.2>
Net income	297.7	220.0	- 77.7	< - 26.1>
R&D expenses	296.4	310.0	+ 13.6	< + 4.6>
E P S	448.81 yen	342.04 yen	- 106.77 yen	< - 23.8>
R O E *	14.4%	10.2%	- 4.2 pt	

* Excluding Extraordinary Income/Loss & Other Extraordinary Factors

< Exchange Rate >

US \$	93 yen	90 yen	- 3 yen
Euro	131 yen	130 yen	- 1 yen


<Ref. Respective impacts for change of 1yen in FY2010>
billions of yen

	US\$	Euro
Net sales	+5.6	+0.8
Operating income	+1.3	+0.4
Net income	+0.7	+0.2

11

Takeda Pharmaceutical Company Limited

Dividend for FY2009 Dividend Forecasts for FY2010



12

Takeda Pharmaceutical Company Limited

Forward-Looking Statements

This presentation contains forward-looking statements regarding the Company's plans, outlook, strategies, and results for the future.

All forward-looking statements are based on judgments derived from the information available to the Company at this time. Forward looking statements can sometimes be identified by the use of forward-looking words such as "may," "believe," "will," "expect," "project," "estimate," "should," "anticipate," "plan," "continue," "seek," "pro forma," "potential," "target," "forecast," or "intend" or other similar words or expressions of the negative thereof.

Certain risks and uncertainties could cause the Company's actual results to differ materially from any forward looking statements contained in this presentation. These risks and uncertainties include, but are not limited to, (1) the economic circumstances surrounding the Company's business, including general economic conditions in the US and worldwide; (2) competitive pressures; (3) applicable laws and regulations; (4) the success or failure of product development programs; (5) decisions of regulatory authorities and the timing thereof; (6) changes in exchange rates; (7) claims or concerns regarding the safety or efficacy of marketed products or product candidates; and (8) integration activities with acquired companies.

We assume no obligation to update or revise any forward-looking statements or other information contained in this presentation, whether as a result of new information, future events, or otherwise.